BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chua R, Keogh AM, Byth K, O’loughlin A. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Internal Medicine Journal 2006;36:705-10. [DOI: 10.1111/j.1445-5994.2006.01169.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen LW, Chen SY, Hsu HH, Wu YW, Lai YM, Chien MY. Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension. Acta Cardiol Sin 2021;37:74-85. [PMID: 33488030 DOI: 10.6515/ACS.202101_37(1).20200720A] [Reference Citation Analysis]
2 Cherniavskiĭ AM, Edemskiĭ AG, Cherniavskiĭ MA, Tarkova AR, Novikova NV, Ivanov SN. [Opportunities of surgical treatment of chronic post-embolic pulmonary hypertension]. Khirurgiia (Mosk) 2016;:76-80. [PMID: 27166479 DOI: 10.17116/hirurgia2016276-80] [Reference Citation Analysis]
3 Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE. The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulm Circ 2017;7:384-90. [PMID: 28597751 DOI: 10.1177/2045893217695568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011;38:608-16. [PMID: 21273391 DOI: 10.1183/09031936.00161410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
5 Santana MJ, S-Parrilla J, Mirus J, Loadman M, Lien DC, Feeny D. An assessment of the effects of Iyengar yoga practice on the health-related quality of life of patients with chronic respiratory diseases: a pilot study. Can Respir J 2013;20:e17-23. [PMID: 23616973 DOI: 10.1155/2013/265406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
6 McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, Mehta S, Murakami N, Wong BA. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53:1801919. [PMID: 30545977 DOI: 10.1183/13993003.01919-2018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 16.3] [Reference Citation Analysis]
7 Mcdonough A, Matura LA, Carroll DL. Symptom Experience of Pulmonary Arterial Hypertension Patients. Clin Nurs Res 2011;20:120-34. [DOI: 10.1177/1054773810391249] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
8 Talwar A, Sahni S, Kim EJ, Verma S, Kohn N. Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients. J Exerc Rehabil 2015;11:259-65. [PMID: 26535216 DOI: 10.12965/jer.150230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kukkonen M, Puhakka A, Halme M. Quality of life among pulmonary hypertension patients in Finland. Eur Clin Respir J 2016;3:26405. [PMID: 26787306 DOI: 10.3402/ecrj.v3.26405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008;5:623-30. [PMID: 18625755 DOI: 10.1513/pats.200802-020SK] [Cited by in Crossref: 67] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
11 Reis A, Twiss J, Vicente M, Gonçalves F, Carvalho L, Meireles J, Melo A, McKenna SP, Almeida L. Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. Health Qual Life Outcomes 2016;14:110. [PMID: 27460644 DOI: 10.1186/s12955-016-0513-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Khan EU. Commentary on symptom experience of pulmonary arterial hypertension (PAH) patients. Clin Nurs Res 2011;20:135-43. [PMID: 21612023 DOI: 10.1177/1054773810395112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Zhou X, Shi H, Yang Y, Zhang Z, Zhai Z, Wang C. Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a Chinese survey. Exp Ther Med 2020;19:3124-32. [PMID: 32256800 DOI: 10.3892/etm.2020.8566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Matura LA, Mcdonough A, Carroll DL. Predictors of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Arterial Hypertension: . Journal of Hospice & Palliative Nursing 2012;14:283-92. [DOI: 10.1097/njh.0b013e3182496c04] [Cited by in Crossref: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Haworth SG. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011;1:280-5. [PMID: 21874157 DOI: 10.4103/2045-8932.83445] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
16 Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest 2009;136:597-603. [PMID: 19666759 DOI: 10.1378/chest.08-1260] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
17 Safdar Z, Tamez E, Frost A, Guffey D, Minard CG, Entman ML. Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. Int J Cardiovasc Res 2015;4. [PMID: 26366423 DOI: 10.4172/2324-8602.1000198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
18 Albanaqi AL, Rahimi GRM, Smart NA. Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biol Res Nurs 2021;23:442-54. [PMID: 33371736 DOI: 10.1177/1099800420982376] [Reference Citation Analysis]
19 Duffels MG, Hardziyenka M, Surie S, de Bruin-bon RH, Hoendermis ES, van Dijk AP, Bouma BJ, Tan HL, Berger RM, Bresser P, Mulder BJ. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension. European Journal of Echocardiography 2009;10:433-8. [DOI: 10.1093/ejechocard/jen308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
20 Hirashiki A, Adachi S, Okumura N, Nakano Y, Shimokata S, Shimizu A, Arai H, Toba K, Murohara T, Kondo T. Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity. Health Qual Life Outcomes 2019;17:103. [PMID: 31200710 DOI: 10.1186/s12955-019-1178-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Pellicer Franco C, Iglesias Neiro P, Piñeiro Corrales G. [Observational study of the efficacy and tolerability of bosentan for the treatment of pulmonary hypertension in a tertiary referral hospital]. Farm Hosp 2007;31:248-52. [PMID: 18052621 DOI: 10.1016/s1130-6343(07)75382-5] [Reference Citation Analysis]
22 Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011;16:1235-40. [PMID: 21810146 DOI: 10.1111/j.1440-1843.2011.02030.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
23 LeVarge BL, Channick RN. The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints. Curr Opin Pulm Med 2015;21:438-45. [PMID: 26176969 DOI: 10.1097/MCP.0000000000000197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Chen YJ, Tu HP, Lee CL, Huang WC, Yang JS, Li CF, Chen CH, Lin KL. Comprehensive Exercise Capacity and Quality of Life Assessments Predict Mortality in Patients with Pulmonary Arterial Hypertension. Acta Cardiol Sin 2019;35:55-64. [PMID: 30713400 DOI: 10.6515/ACS.201901_35(1).20180608A] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med 2015;15:40. [PMID: 25896259 DOI: 10.1186/s12890-015-0031-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
26 Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2011;29:179-88. [PMID: 21045726 DOI: 10.1097/HJH.0b013e328340d76f] [Cited by in Crossref: 110] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
27 Petrovič M, Locatelli I. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension. Ann Pharmacother 2020;54:423-33. [PMID: 31735058 DOI: 10.1177/1060028019888760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Yılmaz BC, Güçlü MB, Keleş MN, Taçoy GA, Çengel A. Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension. Heart Lung 2020;49:564-71. [PMID: 32457004 DOI: 10.1016/j.hrtlng.2020.04.006] [Reference Citation Analysis]
29 Matura LA, Carroll DL. Human responses to pulmonary arterial hypertension: review of the literature. J Cardiovasc Nurs 2010;25:420-7. [PMID: 20714240 DOI: 10.1097/JCN.0b013e3181d25458] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
30 Howard LS, Ferrari P, Mehta S. Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet? Eur Respir Rev 2014;23:458-68. [PMID: 25445944 DOI: 10.1183/09059180.00007514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 Johnson M, Thomson S. The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension. Diseases 2014;2:120-47. [DOI: 10.3390/diseases2020120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
32 Puente-maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, O'donnell DE, Onorati P, Porszasz J, Rabinovich R, Rossiter HB, Singh S, Troosters T, Ward S. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016;47:429-60. [DOI: 10.1183/13993003.00745-2015] [Cited by in Crossref: 208] [Cited by in F6Publishing: 181] [Article Influence: 34.7] [Reference Citation Analysis]
33 Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest 2014;146:686-708. [DOI: 10.1378/chest.13-2634] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
34 McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013;144:522-30. [PMID: 23430021 DOI: 10.1378/chest.12-2443] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
35 Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L'amri M, Gain K, Fowler R, Gabbay E. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med 2013;13:45. [PMID: 23844640 DOI: 10.1186/1471-2466-13-45] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
36 Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs 2014;29:178-84. [PMID: 23151837 DOI: 10.1097/JCN.0b013e318275330d] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
37 Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grünig E, Seyfarth HJ, Kolditz M, Wieder G, Höffken G, Köllner V. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung 2013;191:337-43. [PMID: 23681593 DOI: 10.1007/s00408-013-9472-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
38 Arvanitaki A, Mouratoglou SA, Evangeliou A, Grosomanidis V, Hadjimiltiades S, Skoura L, Feloukidis C, Farmakis D, Karvounis H, Giannakoulas G. Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension. Heart, Lung and Circulation 2020;29:142-8. [DOI: 10.1016/j.hlc.2018.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Rochester CL, Fairburn C, Crouch RH. Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:369-389. [PMID: 24874132 DOI: 10.1016/j.ccm.2014.02.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
40 Duffels MG, Vis JC, van Loon RL, Berger RM, Hoendermis ES, van Dijk AP, Bouma BJ, Mulder BJ. Down patients with Eisenmenger syndrome: Is bosentan treatment an option? International Journal of Cardiology 2009;134:378-83. [DOI: 10.1016/j.ijcard.2008.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
41 Harris A, Cooper BA, Li JJ, Bulfone L, Branley P, Collins JF, Craig JC, Fraenkel MB, Johnson DW, Kesselhut J, Luxton G, Pilmore A, Rosevear M, Tiller DJ, Pollock CA, Harris DC. Cost-Effectiveness of Initiating Dialysis Early: A Randomized Controlled Trial. American Journal of Kidney Diseases 2011;57:707-15. [DOI: 10.1053/j.ajkd.2010.12.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 7.8] [Reference Citation Analysis]
42 Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, Palevsky HI, Taichman DB. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008;102:1431-8. [PMID: 18617379 DOI: 10.1016/j.rmed.2008.04.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
43 Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007;28:75-89, viii. [PMID: 17338929 DOI: 10.1016/j.ccm.2006.11.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
44 Gomberg-maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, Mckenna SP. United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). The Journal of Heart and Lung Transplantation 2008;27:124-30. [DOI: 10.1016/j.healun.2007.10.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]